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Abstract
Background: Type 1 diabetes (T1D) is a chronic, autoimmune and multifactorial disease
characterized by abnormal metabolism of carbohydrate and fat. Diminished carnitine plasma levels
have been previously reported in T1D patients and carnitine increases the sensitivity of the cells to
insulin. Polymorphisms in the carnitine transporters, encoded by the SLC22A4 and SLC22A5 genes,
have been involved in susceptibility to two other autoimmune diseases, rheumatoid arthritis and
Crohn's disease. For these reasons, we investigated for the first time the association with T1D of
six single nucleotide polymorphisms (SNPs) mapping to these candidate genes: slc2F2, slc2F11,
T306I, L503F, OCTN2-promoter and OCTN2-intron.
Methods: A case-control study was performed in the Spanish population with 295 T1D patients
and 508 healthy control subjects. Maximum-likelihood haplotype frequencies were estimated by
applying the Expectation-Maximization (EM) algorithm implemented by the Arlequin software.
Results: When independently analyzed, one of the tested polymorphisms in the SLC22A4 gene at
1672 showed significant association with T1D in our Spanish cohort. The overall comparison of the
inferred haplotypes was significantly different between patients and controls (χ2 = 10.43; p = 0.034)
with one of the haplotypes showing a protective effect for T1D (rs3792876/rs1050152/rs2631367/
rs274559, CCGA: OR = 0.62 (0.41–0.93); p = 0.02).
Conclusion: The haplotype distribution in the carnitine transporter locus seems to be significantly
different between T1D patients and controls; however, additional studies in independent
populations would allow to confirm the role of these genes in T1D risk.
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Type 1 diabetes (T1D) is a multifactorial autoimmune T-
cell-mediated disease resulting from selective destruction
of the insulin producing β cells in the pancreatic islets,
leading to an absolute insulin deficiency. The risk of
developing T1D is determined by a complex interaction
between multiple genetic and environmental factors.
Although susceptibility to disease is strongly associated
with alleles in the major histocompatibility complex
(MHC) [1,2], there are more than 20 putative T1D suscep-
tibility regions identified by linkage and association stud-
ies [3,4]. At present, several non-MHC susceptibility loci
with modest genetic effects have been clearly defined.
However, it is well known that many non-MHC loci pre-
disposing to T1D remain as yet undefined [5].
Type 1 diabetes is a chronic degenerative disease, with
altered metabolism characterized by hyperglycemia and
ketoacidosis and T1D patients depend on exogenous insu-
lin to sustain life. The role of the carnitine system in cell
metabolism is mainly known in the mitochondria, where
the interaction between fatty acid and glucose metabolism
is fundamental for cell energy production [6,7]. However,
carnitine not only contributes to the transport of activated
long-chain fatty acids into mitochondria for β-oxidation,
but it also increases the sensitivity of cells to insulin [8].
Decreased plasma carnitine levels have been reported in
patients with type 2 diabetes [9-11] and some studies have
investigated the carnitine status in T1D, finding similar
results [12-15].
Adequate carnitine levels are required for normal lipid
metabolism and are important for energy metabolism
[16]. One important component of the carnitine system is
the plasma membrane carnitine transporters, named
organic cation transporters (OCTN1 and OCTN2)
encoded by the SLC22A4 and SLC22A5 genes, respec-
tively. Both genes map to the cytokine gene cluster on
chromosome 5q31 and show 88% homology and 77%
identity in their sequences. Despite OCTN1 and OCTN2
are considered as carnitine transporters, only OCTN2 is a
high-affinity human carnitine transporter, while the carni-
tine transport activity of OCTN1 is very low [17,18]. In
fact, a recent study has reported that the main substrate of
this transporter is the ergothioneine, an intracellular anti-
oxidant with metal ion affinity, which is transported one
hundred times more efficiently than carnitine [18].
OCTN2 is widely expressed in many adult tissues, among
them in pancreas, and it participates, at least in part, in
proton/organic cation antiport at the renal apical plasma
membrane level [19].
Recent reports performed associations of some polymor-
phisms within the SLC22A4 and SLC22A5 genes with two
other autoimmune complex diseases (rheumatoid arthri-
tis and Crohn's disease) [20,21]. The purpose of this study
was to investigate the influence of the SLC22A4 and
SLC22A5 genes in type 1 diabetes risk in the Spanish pop-
ulation. Six SNPs along these genes were considered good
markers to map this region: slc2F2 (rs3792876) and
slc2F11 (rs 2306772), which are SNPs in the SLC22A4
gene, were originally associated with RA susceptibility
[20]. Other polymorphisms within the same linkage dise-
quilibrium (LD) block (slc2F1) and slc2F2 showed lack of
association with T1D [22]. We have studied two addi-
tional SNPs in this gene: T306I (rs272893) and L503F
(rs1050152, SNP located in exon 9 of SLC22A4). The
OCTN2-promoter (rs2631367) is a transversion (-
207G>C) disrupting a heat shock element in the promoter
region of the SLC22A5 gene and it has been described,
together with L503F, as etiologic variant in Crohn disease
[21]. Finally, we analyzed an intronic SNP in the SLC22A5
gene: the OCTN2-intron (rs274559) in order to define
haplotypes within these genes.
Methods
Patients
We studied 295 unrelated Spanish white T1D patients
(149 men and 146 women) diagnosed according to the
criteria of the American Diabetes Association (ADA) and
508 healthy controls recruited among blood donors. Both
groups ethnically matched from the Madrid area. The age
at onset for the T1D patients range from 1 to 55 years old
(median age at onset 15 years) and all subjects were insu-
lin-dependent at the time to study. The protocol followed
the principles expressed in the Declaration of Helsinki
and it was approved by the Hospital Ethics Committee.
SNP genotyping
SNPs slc2F2 (rs3792876), slc2F11 (rs2306772), T306I
(rs272893), L503F (rs1050152) and OCTN2-intron
(rs274559) were genotyped by TaqMan Assays on
Demand under conditions recommended by manufac-
turer (Applied Biosystems), with identification numbers:
C__3170428_10, C__3170458_1_, C__3170445_1_,
C__3170459_10 and C__1173605_1, respectively. For
the SLC22A5 promoter -207G>C (rs2631367), a TaqMan
Assay by Design was performed.
Statistical analysis
Differences in allele or genotype frequencies for each
marker were calculated by Chi-square, or Fisher's exact
test when necessary. Associations were estimated by the
odds ratio (OR) with 95% confidence interval (CI). Statis-
tical analysis used Epi Info v. 6.02 (CDC Atlanta USA).
Maximum-likelihood haplotype frequencies were esti-
mated by applying the Expectation Maximization (EM)
algorithm implemented by the Arlequin software [23],
with number of iterations set at 5000 and initial condi-Page 2 of 6
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yields the estimated frequency of each haplotype, but it
does not output the expected haplotypes for each individ-
ual. The frequency data were transformed into absolute
numbers multiplying the frequencies presented in Table 3
by the total number of haplotypes in each group (patients
and controls). Then, these values were introduced into
contingency tables to calculate Chi-square and p-values.
Results
Six SNPs were studied in order to check the role of
SLC22A4 and SLC22A5 genes in T1D predisposition (see
figure 1). Slc2F2, Slc2F11, T306I and L503F map in the
SLC22A4 gene and two additional SNPs, OCTN2-pro-
moter and OCTN2-intron, are located in the SLC22A5
gene. The analysis of the control cohort showed complete
linkage disequilibrium (LD) between Slc2F11 and slc2F2,
and T306I was also found in complete LD with OCTN2-
intron. Both SNPs (slc2F11 and T306I) were not consid-
ered in the subsequent case-control study, because they do
not supply additional information. These polymorphisms
conformed to Hardy-Weinberg equilibrium.
The association of the intronic slc2F2 polymorphism in
the SLC22A4 gene with rheumatoid arthritis (RA) was
originally reported in a Japanese population [20]. This
SNP was even described as an etiological variant in Japan,
being the mutant homozygous genotype (slc2F2*TT)
associated with RA. However, this association could not
be replicated either in British [24] or in Spanish popula-
tions [25]. Table 1 shows the phenotype and genotype
distribution of this marker in the Spanish T1D patient and
control cohorts, and lack of significant association with
the disease was observed. The allelic distribution was sim-
ilar to that previously observed in Spanish RA patients,
(minor allele frequency slc2F2*T was 7.5% in RA and
9.5% in T1D patients). We tested the carrier rate of this
allele (CT+TT vs. CC) to find a possible association with
T1D, but a negative result was again obtained: OR = 1.30
(0.87–1.94); p = 0.17.
Regarding the L503F (1672G>C) polymorphism, it was
described by Peltekova et al. [21] as a functional variant
associated with Crohn's disease, together with the
OCTN2-promoter (-207G>C) variant. In fact, the authors
found that the odds ratios conferred by the allele 1672*T,
by the allele -207*C or by the TC minihaplotype were all
similar. Both polymorphisms were also in strong linkage
disequilibrium in our population (D' = 0.86) [26]. How-
ever, their etiological role could not be verified in Spanish
Crohn's patients and they were not described as causative
polymorphisms, but as genetic markers of risk or protec-
tion haplotypes. In our diabetic population, the allele
1672*T increased disease predisposition [OR = 1.25
(1.01–1.54); p = 0.034] and the 1672*CC genotype
showed a protective effect (Table 1), but no significant dif-
ferences between patients and controls were found for
alleles and genotypes of the OCTN2-promoter (-207G>C)
and of the other SLC22A5 intronic variant (Table 2).
We continued our study by analyzing the inferred
OCTN1-OCTN2 haplotypes, since haplotypes define bet-
ter a DNA fragment where a susceptibility or protective
gene could be located. Table 3 shows the haplotypes esti-
mated by the Expectation-Maximization (EM) algorithm
implemented by the Arlequin software with a frequency
over 1%. The overall comparison of haplotypes in a 5 × 2
contingency table rendered a significant difference
between patients and healthy controls (χ2 = 10.43; p =
0.034), and being a unique omnibus comparison, this
result does not need ulterior correction. These results evi-
denced one protection CCGA [OR = 0.62 (0.41–0.93); p =
0.02] and another risk CTCA [OR = 1.23 (1.00–1.52); p =
0.05] haplotypes, although they did not withstand correc-
tion for multiple testing (Table 3). The effect of the latter
is secondary to the protective haplotype, as evidenced
when this one is eliminated from the comparison and no
significant predisposition effect was observed [OR = 1.16
(0.93–1.44); p = 0.18]; however, when the eliminated
haplotipe is CTCA, a significant protection effect is still
found for the CCGA haplotype [OR = 0.67 (0.44–1.02); p
Schematic representation of the chromosomal region 5q31 with the relative position of the polymorphisms studiedFigure 1
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1672*C allele do not show any influence in T1D predis-
position, the protective effect of the 1672*C allele (p =
0.034) is due to this CCGA haplotype.
To complete the study in our population, we analyzed
children and adolescents with type 1 diabetes fixing the
cut-off age in 15 years old (median age at onset in our
cohort). No differences between young patients and either
adult patients or controls were found for any isolated var-
iant or for the inferred haplotypes (data not shown).
Finally, the frequencies of both, polymorphisms and
inferred haplotypes, between male and female T1D
patients were similar (data not shown).
Discussion
The chromosomal region 5q31 contains several genes
involved in immune and inflammatory responses and the
SLC22A4 and SLC22A5 genes were associated with two
autoimmune diseases (rheumatoid arthritis and Crohn's
disease) [20,21]. Additionally, several genomewide scans
for type 1 diabetes have identified susceptibility loci on
different chromosomes, including the region 5q [27,28].
Moreover, carnitine has been described to increase sensi-
tivity of cells to insulin [8], which could hypothetically
lend cells more prone to an autoimmune attack. For all
these reasons we considered that these genes could be can-
didates to modify the susceptibility to another autoim-
mune disease, as type 1 diabetes.
We tested six polymorphisms in the SLC22A4 and
SLC22A5 genes and in five of them no significant inde-
pendent association with type 1 diabetes could be found
(Tables 1 and 2). The power of this study considering a
relative risk of 1.5 was 75% for Slc2F2, 86% for L503F and
99% for OCTN2-promoter and OCTN2-intron, as calcu-
lated by an UCLA Department of Statistics sofware [29].
Therefore, we can exclude the studied SLC22A5 markers as
causative candidates for T1D in Spanish patients, but in
the case of Slc2F2 our results are not conclusive, albeit a
recently published study does not find association of
Slc2F1 and Slc2F2 SLC22A4 polymorphisms within a
well-powered T1D cohort [22], in agreement with our
data.
The overall distribution of the estimated haplotypes was
significantly different between patients and healthy con-
trols. Being ours the first study carried out in T1D, replica-
tion studies in different T1D populations would be
necessary to firmly establish the role of these genes in
autoimmune diabetes. We proved by using a stepwise pro-
cedure that the association with T1D of the protection
haplotype CCGA is primary. The etiological polymor-
phisms previously found associated with increased sus-
ceptibility to RA (slc2F2*T) and to Crohn's disease
(L503F*T) do not display a causative role by themselves
in our population.
Low carnitine plasma levels have been found in children
and adolescents with type 1 diabetes [12,13,15]. For this
reason, we decided to conclude the study with an age-
stratified analysis. No significant differences in the associ-
ation of each polymorphism were observed when group-
ing by age at onset or gender. In the study of the inferred
haplotypes again no differences were found between any
group of patients and when we compared each group with
controls. Therefore, it seems that the protective effect of
Table 1: Genotype and phenotype frequency distribution for 
OCTN1 markers.
Slc2F2 T1D (%) Controls (%)
Alleles 2n = 590 2n = 1016
C 534 (90.5) 938 (92.3)
T 56 (9.5) 78 (7.7)
Genotypes n = 295 n = 508
CC 240 (81.4) 432 (85)
CT 54 (18.3) 74 (14.6)
TT 1 (0.3) 2 (0.4)
L503F T1D (%) Controls (%)
Alleles 2n = 590 2n = 970
C 299 (50.7) 545 (56.2)
T 291 (49.3) 425 (43.8)
Genotypes n = 295 n = 485
CC* 69 (23.4) 156 (32.2)
CT 161 (54.6) 233 (48.0)
TT 65 (22.0) 96 (19.8)
*OR = 0.64 (0.46–0.91); p = 0.009
Table 2: Distribution of OCTN2 polymorphisms.
OCTN2 Promoter T1D (%) Controls (%)
Alleles 2n = 590 2n = 1016
C 327 (55.4) 533 (52.5)
G 263 (44.6) 483 (47.5)
Genotypes n = 295 n = 508
CC 91 (30.8) 150 (29.5)
CG 145 (49.2) 233 (45.9)
GG 59 (20.0) 125 (24.6)
OCTN2 Intron T1D (%) Controls (%)
Alleles 2n = 590 2n = 1016
A 370 (62.7) 636 (62.6)
G 220 (37.3) 380 (37.4)
Genotypes n = 295 n = 508
AA 115 (39.0) 194 (38.2)
AG 142 (48.1) 248 (48.8)
GG 38 (12.9) 66 (13.0)Page 4 of 6
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at disease onset.
A previous report about disequilibrium blocks at 5q31 in
European-derived population [30] demonstrated limited
haplotype diversity, concordantly with our data (5 haplo-
types found out of the 24 = 16 theoretically possible). One
of the defined blocks (92 kb long) corresponds to the car-
nitine transporter genes locus. These authors indicated
that the chromosomal region 5q31 is divided into discrete
blocks displaying complete linkage disequilibrium (LD).
However, some degree of LD extending beyond the
SLC22A4 and SLC22A5 genes could imply that most
probably these genes, or other in LD with them, are
responsible for the reported effect on T1D risk.
Conclusion
In conclusion, the overall comparison of haplotypes
within the chromosomal region where the carnitine trans-
porter genes map seems to be different between type 1
diabetes patients and healthy controls in our Spanish
population. The reduced carnitine plasma levels found in
both type 1 and type 2 diabetes patients [12,13] could be
explained by a mere increase in the activity of the carnitine
transporters to supply the higher energetic cellular
demand mainly provided by lipid metabolism in young
diabetes patients. However, our results with the 1672*C
allele and with the inferred haplotypes, the effect of carni-
tine sensitizing cells to insulin and potentially rendering
them more amenable to an immune attack, and also the
LD-block data described by Daly [30], support the role of
the OCTN genes in T1D risk. Additional studies in inde-
pendent populations and in both type 1 and type 2 diabe-
tes patients will be needed to confirm the putative
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